MedTrace Logo

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

NCT06298266 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-03-07

No results posted yet for this study

Summary

To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma

Conditions

Interventions

BIOLOGICAL

infusion of GPRC5D-CD19 CAR T injection

Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Sponsors & Collaborators

  • Guangdong Second Provincial General Hospital

    lead OTHER

Principal Investigators

  • Qing Zhang, Doctoral · Guangdong Second Provincial General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-29
Primary Completion
2026-05-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06298266 on ClinicalTrials.gov